Talk:Tigilanol tiglate
Appearance
This is the talk page for discussing improvements to the Tigilanol tiglate article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tigilanol tiglate.
|
Untitled
[edit]Presumably EBC-46 is the same compound as EBI-46 listed in the patent, but stereochemistry is not given (and obviously very important given the structure), and the chemical name is definitely not IUPAC standard! Meodipt (talk) 12:57, 2 February 2011 (UTC)
- Stereochemistry is given on PubChem for a closely related natural product Mancinellin, so for the time being I have redrawn the structure with the same stereochemistry for EBC-46 (plus missing methyl group). Meodipt (talk) 22:45, 2 February 2011 (UTC)
Considering Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. -- should this article state that EBC-46 is an activator or modulator, not a regulator as it presently states? Zipf (talk) 03:03, 6 April 2015 (UTC)
News Sources
[edit]A couple news source links if anyone wants to use them: